Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure hope? major trial tests Selenium's power

NCT ID NCT07543562

Disease control Sponsor: Skane University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a daily selenium supplement (200 micrograms) can reduce hospitalizations and heart-related deaths in people with heart failure. Selenium is a nutrient important for heart health, and low levels are common in Northern Europe. The trial will include over 4,300 adults in Sweden and Norway who are already receiving standard heart failure care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 4,326 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To be considered for inclusion in this study, patients must meet all of the following eligibility requirements: * 18 years of age * primary discharge diagnosis of HF coded as ICD-10: I50, as recorded in The SwedeHF registry * be able to provide documented informed consent by signing and dating the designated consent form. Exclusion Criteria: * Not suitable in the opinion of the Investigator (for example due to severe or terminal comorbidity with poor prognosis, or characteristics, pregnancy etc.) that may interfere with adherence to trial protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive functioning are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive functioning Heart failure Heart failure and mildly reduced ejection fraction Heart failure and preserved ejection fraction Heart failure and reduced ejection fraction Selenium Selenium supplementation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akademiska University hospital

    RECRUITING

    Uppsala, Sweden

  • Karolinska University Hospital

    RECRUITING

    Stockholm, Sweden

  • Linköping University Hospital

    RECRUITING

    Linköping, Sweden

  • Norrlands university Hospital

    RECRUITING

    Umeå, Sweden

  • Oslo University Hospital

    RECRUITING

    Oslo, Norway

  • Ryhov Hospital

    RECRUITING

    Jönköping, Sweden

  • Sahlgrenska

    RECRUITING

    Gothenburg, Sweden

  • Sahlgrenska University Hospital Östra

    RECRUITING

    Gothenburg, Sweden

  • Skånes University Hospital

    RECRUITING

    Malmö, Skåne County, Sweden

  • Skånes University Hospital

    RECRUITING

    Lund, Sweden

  • Örebro University Hospital

    RECRUITING

    Örebro, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.